Eli Lilly And Co’s (NYSE:LLY) CEO, David Ricks, shared the pharmaceutical giant’s plans to introduce its obesity drug, tirzepatide, in India as early as next year.
Tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss in the United States, holds promise for the Indian market.
Ricks underscored the need for India to enhance patent protection, eliminate redundant policies, and establish a robust social safety net to attract increased investments from global pharmaceutical companies.
Citing Ricks’ remarks at the BioAsia conference, Reuters highlighted the pivotal factors that could drive more significant participation from international drugmakers in India.
Lilly faces competition in the diabetes and weight-loss drug space from Danish rival Novo Nordisk A/S (NYSE:NVO).
Last year, a senior executive from Novo Nordisk disclosed plans to introduce Wegovy, their blockbuster weight-loss drug, to the Indian market by 2026.
As pharmaceutical companies like Eli Lilly and Novo Nordisk continue to expand their reach and bring innovative solutions to diverse markets, India emerges ...